Wall Street analyst estimates for Evogene Ltd. (EVGN): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Evogene Ltd., along with its subsidiaries, operates as a computational biology firm. Its core activity involves the discovery and advancement of products across diverse life-science sectors, such as human health and agriculture, primarily leveraging its proprietary Computational Predictive Biology (CPB) platform.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 4 |
| Hold | 0 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 4 |
| Avg rating (1-5) | 1.00 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-18 | $-0.27 | ||
| 2026-08-18 | $-0.13 | $-0.27 | +51.9% |
| 2026-05-20 | $-0.60 | $-0.27 | -122.2% |
| 2026-03-05 | $-0.61 | $-0.26 | -134.6% |
| 2025-11-20 | $-0.31 | $-0.26 | -19.2% |
| 2025-08-19 | $-0.62 | $-0.63 | +1.6% |
| 2025-05-21 | $-0.38 | $-0.62 | +39.2% |
| 2025-03-06 | $0.06 | $-0.72 | +108.3% |
Valuation Ratios
| Price / Book | -1.98 |
| EV / EBITDA | 0.19 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $6.5M | $3.4M | $1.7M | $753000 | $1.0M | $930000 | $1.7M | $3.0M | $5.6M | $3.9M |
| Cost of Revenue | $5.6M | $2.8M | $1.5M | $334000 | $574000 | $767000 | $909000 | $1.5M | $2.4M | $4.1M |
| Gross Profit | $901000 | $536000 | $295000 | $419000 | $466000 | $163000 | $766000 | $1.5M | $3.2M | -$241000 |
| Research & Development | $16.4M | $17.0M | $14.7M | $15.8M | $17.3M | $21.1M | $20.8M | $16.2M | $12.5M | $8.0M |
| Selling, General & Admin | $5.6M | $5.5M | $5.6M | $5.8M | $8.0M | $10.0M | $10.4M | $7.5M | $9.0M | $5.8M |
| Operating Expenses | $22.0M | $22.5M | $20.3M | $21.6M | $25.3M | $31.1M | $27.7M | $23.7M | $22.0M | $13.8M |
| Operating Income | -$21.1M | -$21.9M | -$20.0M | -$21.2M | -$24.8M | -$31.0M | -$26.9M | -$22.2M | -$18.8M | -$14.0M |
| EBITDA | -$18.8M | -$18.7M | -$18.8M | -$16.0M | -$23.2M | -$27.9M | -$27.0M | -$20.5M | -$13.4M | -$12.2M |
| Interest Expense | $155000 | $129000 | $141000 | $354000 | $269000 | $403000 | $241000 | $171000 | $124000 | $1.9M |
| Pre-tax Income | -$19.6M | -$20.8M | -$20.8M | -$19.1M | -$26.2M | -$30.4M | -$29.8M | -$21.9M | -$14.8M | -$13.5M |
| Income Tax | $36000 | $11000 | $30000 | $24000 | $32000 | $13000 | $90000 | $19000 | $9000 | $1000 |
| Net Income | -$19.6M | -$20.8M | -$20.8M | -$18.1M | -$23.4M | -$27.8M | -$26.6M | -$23.9M | -$16.5M | -$8.5M |
| EPS | $-0.77 | $-0.81 | $-0.81 | $-0.70 | $-0.64 | $-0.68 | $-6.46 | $-5.23 | $-2.89 | $-1.08 |
| EPS (Diluted) | $-0.77 | $-0.81 | $-0.81 | $-0.70 | $-0.64 | $-0.68 | $-6.46 | $-5.23 | $-2.89 | $-1.08 |
| Shares Outstanding (Diluted) | $25.4M | $25.7M | $25.8M | $25.8M | $36.6M | $41.0M | $4.1M | $4.6M | $5.7M | $7.9M |
Price
| Price | $0.50 |
| Market Cap | $4M |
| Exchange | NASDAQ |
| Country | IL |
Related companies: AEON · BOLT · CING · CLRB · COCP · DWTX · GLTO
Explore sector: Healthcare · Biotechnology
More sections of EVGN: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks